Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248299 | 0.87 | MTNR1A (0.40) | MTNR1AMTNR1BHTR6MAPTTAAR1 | |
| SCHEMBL3253643 | 0.86 | MTNR1A (0.39) | MTNR1AMTNR1BHTR6NPC1MAPT | |
| SCHEMBL3253659 | 0.86 | MTNR1A (0.42) | MTNR1AMTNR1BHTR6TAAR1 | |
| SCHEMBL3251139 | 0.86 | MTNR1A (0.42) | MTNR1AMTNR1BHTR6NPC1MAPT | |
| SCHEMBL3253753 | 0.85 | MTNR1A (0.45) | MTNR1AMTNR1BHTR6MAPT | |
| SCHEMBL3250887 | 0.85 | HTR7 (0.43) | MTNR1AMTNR1BHTR6MAPT | |
| SCHEMBL3252526 | 0.83 | MTNR1A (0.40) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL3253540 | 0.81 | MTNR1A (0.61) | MTNR1AMTNR1BHTR6 | |
| Dimethylamine SCHEMBL3253217 | 0.81 | MTNR1A (0.42) | MTNR1AMTNR1BNPC1MAPTRAB9A | |
| SCHEMBL3251308 | 0.79 | MTNR1A (0.35) | MTNR1AMTNR1BHTR6NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | claimed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | claimed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | claimed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | claimed |
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | disclosed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | disclosed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | MTNR1A 76/4885MTNR1B 105/4885HTR6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.